Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Comparative Analysis of Butter, Ghee, and Margarine and Its Implications for Healthier Fat and Oil Group Choices: SWOT Analysis.

Food science & nutrition·2024
Same author

Soluble class I antigens: a conundrum with no solution?

Immunology today·2014
Same author

Regulation of CD1 function and NK1.1(+) T cell selection and maturation by cathepsin S.

Immunity·2002
Same author

Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells.

Journal of virology·2001
Same author

Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells.

The Journal of experimental medicine·2001
Same author

A novel immunoadsorption device for removing beta2-microglobulin from whole blood.

Kidney international·2001

Related Experiment Video

Updated: Sep 6, 2025

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
08:09

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

Published on: April 6, 2015

11.7K

Nanobodies as non-invasive imaging tools.

M Rashidian1, H Ploegh2

  • 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.

Immuno-Oncology Technology
|June 27, 2022
PubMed
Summary

Nanobodies, the smallest antibody fragments, are emerging as powerful tools for cancer imaging. Their unique properties enable non-invasive visualization of immune responses and cancer biomarkers, guiding patient treatment.

Keywords:
ImmunoPETPET imagingcancer biomarkersimmunotherapynanobodynon-invasive imaging

More Related Videos

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

10.4K
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.4K

Related Experiment Videos

Last Updated: Sep 6, 2025

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
08:09

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy

Published on: April 6, 2015

11.7K
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

10.4K
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.4K

Area of Science:

  • Immunology
  • Biotechnology
  • Medical Imaging

Background:

  • Antibodies and antibody fragments are crucial for diagnostics and therapeutics.
  • Nanobodies (heavy-chain variable domains) are the smallest antibody fragments with antigen-binding capabilities.
  • Their discovery approximately 30 years ago has led to novel applications.

Purpose of the Study:

  • To review recent advancements in using nanobodies as cancer imaging agents.
  • To highlight the potential of nanobodies in non-invasively imaging immune responses and cancer biomarkers.
  • To discuss their value in guiding cancer treatment decisions.

Main Methods:

  • Review of preclinical and early clinical studies on nanobody applications in cancer imaging.
  • Analysis of nanobody characteristics (size, stability, specificity, affinity, manufacturability) for imaging.
  • Examination of nanobody utility in the context of cancer immunotherapy.

Main Results:

  • Nanobodies offer advantages as imaging agents due to their small size, stability, and specificity.
  • Significant progress has been made in preclinical models for cancer imaging.
  • Initial human applications are demonstrating the clinical value of nanobodies.

Conclusions:

  • Nanobodies represent a promising class of agents for cancer imaging.
  • Their ability to visualize biomarkers and immune responses is crucial for personalized cancer therapy.
  • Further clinical translation is expected to solidify their role in oncology.